Who is the real Andrés Manuel López Obrador (AMLO)? The man of the people who promises to abolish the “manifest failure and corruption of neoliberal policies”, or the fiscally-responsible statesman who promises a New Deal for Mexico? The answer to this riddle may give some pointers as to the course AMLO will steer over the six years of his presidency.
Commodity prices could be pressured for several more years.
With a new year underway, here’s our five-point guide for what we believe is in store for European high yield markets in 2019:
China’s A-shares are at crisis-level valuations for an economy that is still growing faster than most places around the world. Indiscriminate stock selling by local investors on the back of trade tensions with the US have left China’s A-share market trading at less than ten times earnings compared to 16 times a year ago. Such valuations provide compelling investment opportunities for the long term.
Upon returning from our November 2017 research visit to Kuwait, we felt confident the economy was on improved footing after what had been an extended hangover from the 2008 financial crisis. However, what stopped us from getting more excited at the time was the fact many stocks had rallied hard on FTSE Russell’s announcement to move Kuwait to its Emerging Markets Index. Despite some positive meetings and witnessing companies making decent fundamental improvements, valuations appeared rich and we felt comfortable maintaining our significant country-level underweight.
Watch Templeton Global Macro’s Head of Research, Sonal Desai, discuss the impact of rising US rates and currency considerations in emerging markets.
Asset management is all about trust as emerging market (EM) specialists at LGM, part of BMO Global Asset Management, explain in this video. They go on to describe the fundamentals for the EM investment case, and why they are so strong. As lead portfolio manager, Rishikesh Patel said: “Some 75% of the world’s population are […]
Analyst and Portfolio Manager at BB Biotech since 2014. Dr. Koch previously worked as a sell-side Pharma & Biotech Equity Analyst at Bank am Bellevue and Research Associate at the Institute of Pharmaceutical Sciences, ETH Zurich. He holds a PhD in Chemoinformatics & Computational Drug Design from ETH Zurich and a Masters in Bioinformatics from Goethe University Frankfurt.
Success in challenging fixed income markets requires an approach that is truly unconstrained.
Nick Payne, head of global emerging markets at Old Mutual Global Investors, feels more sanguine about his asset class now that the exuberant start to 2018 has eased.